- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510739
Support for Physical Activity in Everyday Life With Parkinson's Disease (STEPS-PD)
Support for Physical Activity in Everyday Life With Parkinson's Disease Using eHealth Technology
Study Overview
Status
Detailed Description
This randomised controlled trial will investigate the efficacy of a motor-cognitive exercise program in the home environment, over a 10-week period, on physical function, and motor-cognitive dual task function as well as physical activity behavior in everyday life. A follow-up assessment comprising health-related questionnaires and physical activity monitoring will be conducted at one year post-intervention. Participants will be recruited through Stockholms sjukhem foundation, Karolinska University and via announcements in relevant forums like for instance the Swedish Parkinson Association. Consenting participants will be randomized to the eHealth Intervention group or the control group condition. Block randomization will be achieved using a computerized random sequence generator. Blinded assessors will perform the pre- and post-intervention testing of physical performance.
The ultimate aim of this project is to provide people with PD with continual long-term and evidence-based rehabilitation in their everyday lives using mobile health technology, to support their self- management and increase their quality of life.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 141 83
- Stockholms sjukhem
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson´s disease
- Hoehn & Yahr (Parkinsons progression scale) 1-3
- ≥ 50 years of age
- Able to ambulate indoors without mobility aid
- Able to walk continually with/without a walking aid for at least 6 minutes
Exclusion Criteria:
- Cognitive impairment affecting the ability to understand or follow verbal or written instructions (Montreal Cognitive Assessment ≤ 21 points
- Major problems with freezing and/or two or more falls in the month previous to inclusion
- Other existing neurological/ orthopedic or cardiovascular disease which impedes the performance of unsupervised exercise
- Impaired vision and/or impaired communication which hinders participation
- No internet connection in the home
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Motor-cognitive exercise using eHealth
10-week eHealth based motor-cognitive home training using digital tablets.
Cognitive behavioural strategies to promote increase in physical activity levels (walking).
Participants will be encouraged to perform 150 minutes of home exercise per week, occurring on three non-consecutive days.
|
10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels.
Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
|
|
Active Comparator: Individualised home training program
Participants will receive an individualized home exercise program on paper and one instructional session.
They will receive written instructions on performing the program 2-3 times weekly and instructions on exercise progression.
They will receive no support during the 10-week period.
|
Individualised home exercise program leaflet involving one initial instruction session.
Written instructions involving dose and exercise progression.
No support during the 10 week period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The six minute walk test
Time Frame: Change in balance performance at 10 weeks
|
This test measures walking capacity by measuring the distance covered (meters) over a time period of 6 minutes.
|
Change in balance performance at 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gait parameters during single and dual-task conditions
Time Frame: Change at 10 weeks
|
Stride length (meters); Cadence (steps/ minute) will be captured using born-worn inertial sensors
|
Change at 10 weeks
|
|
Dual-task ability during walking
Time Frame: Change at 10 weeks
|
Captured using the Auditory Stroop test during walking and expressed as percentage error of the task
|
Change at 10 weeks
|
|
Executive function
Time Frame: Change at 10 weeks
|
Trail making test A & B. Expressed as time required to perform the test (seconds)
|
Change at 10 weeks
|
|
Quality of life questionnaires
Time Frame: Change at 10 weeks and one year post-intervention
|
PDQ-39 is disease specific quality of life questionnaire.
Items are grouped into eight scales that are scored by expressing summed item scores as a percentage score ranging between 0 and 100
|
Change at 10 weeks and one year post-intervention
|
|
Physical activity measured with accelerometers
Time Frame: Change at 10 weeks and one year post-intervention
|
Steps per day and time (minutes) in different physical activity intensities (high,moderate and low intensity)
|
Change at 10 weeks and one year post-intervention
|
|
Balance ability
Time Frame: Change at 10 weeks
|
MiniBest test.
Scoring 0-28, lower scores = greater balance impairment
|
Change at 10 weeks
|
|
Balance Confidence
Time Frame: Change at 10 weeks and one year post-intervention
|
The Activities-specific Balance Confidence scale is a measure of confidence performing in various activities without losing balance or experiencing unsteadiness.
A 16-item self-report measure with items rated on a rating scale that ranges from 0-100.
A higher score indicates higher balance confidence.
|
Change at 10 weeks and one year post-intervention
|
|
Health-related Quality of Life
Time Frame: Change at 10 weeks and one year post-intervention
|
The EQ-5D is a two-part instrument that measures health-related quality of life.
It examines 5 domains of quality of life: mobility, self-care, daily activities, pain, anxiety/depression.
It comprises 5 questions and a visual scale.
|
Change at 10 weeks and one year post-intervention
|
|
Exercise Self-Efficacy
Time Frame: Change at 10 weeks and one year post-intervention
|
The Exercise Self-Efficacy Scale is an instrument examining confidence regarding carrying out regular physical activities and exercise.
Questions are answered on a 4-point rating scale.
A higher score indicates greater confidence.
|
Change at 10 weeks and one year post-intervention
|
|
Walking ability
Time Frame: Change at 10 weeks and one year post-intervention
|
The Walk-12 questionnaire examines limitations in walking ability.
It consists of 12 questions answered on either a 3-point or 5-point rating scale.
|
Change at 10 weeks and one year post-intervention
|
|
Hospital Anxiety and Depression Scale
Time Frame: Change at 10 weeks and one year post-intervention
|
A 14-item measure designed to reflect the state of generalised anxiety and depression.
The respondent rates each item on a 4-point scale.
Higher scores indicate greater levels of anxiety or depression.
|
Change at 10 weeks and one year post-intervention
|
|
Life Space Assessment
Time Frame: Change at 10 weeks and one year post-intervention in only the final cohort of participants
|
The LSA is a self-report measure of the frequency of independent mobility across 5 life-space levels.
Higher scores indicate more life-space and movement throughout the community.
|
Change at 10 weeks and one year post-intervention in only the final cohort of participants
|
|
Global Positioning System
Time Frame: Change at 10 weeks and one year post-intervention in only the final cohort of participants
|
GPS monitors collecting participant daily location and movement data via latitude and longitude coordinates collected throughout waking hours.
|
Change at 10 weeks and one year post-intervention in only the final cohort of participants
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Maria Ankarcrona, PhD, Karolinska Institutet, NVS
- Study Chair: Sofia Pettersson, MSc, Stockholms Sjukhem Foundation, Primary Care Rehabilitation
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Synucleinopathies
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurodegenerative Diseases
- Movement Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Pathological Conditions, Signs and Symptoms
- Behavior
- Signs and Symptoms
- Parkinson Disease
- Gait Disorders, Neurologic
- Motor Activity
Other Study ID Numbers
- StockholmsSjukhem
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.